Featured News
Glycovax Pharma and Université Laval to develop innovative inhibitors targeting galectin-3
Idiopathic pulmonary fibrosis (IPF) affects approximately 15,000 people in Canada, 100,000 in the United States, and 200,000 in Europe, while nonalcoholic steatohepatitis (NASH) affects approximately 38 million Americans, 10 million Europeans, and 1.5 million Canadians. Professor Denis Giguère, from the Department of Chemistry at Université Laval, an expert in carbohydrate chemistry and complex molecule design,…
Glycovax, the NRC and the Université de Montréal develop a vaccine against the bacterium Pseudomonas aeruginosa (Pa), with support from CQDM
Respiratory diseases—which develop particularly in hospitals, such as those resulting from Pa infections—remain a scourge for which there is currently no effective vaccine. Often resistant to antibiotics, Pa infection is a leading cause of hospital-acquired illness and of infections that are sometimes fatal in people with cystic fibrosis. Glycovax Pharma has optimized manufacturing of the…
Glycovax Pharma Granted NRC Licence to Develop Pseudomonas aeruginosa Vaccine
Glycovax Pharma has been granted a strategic licence by the NRC to develop a semisynthetic vaccine targeting Pseudomonas aeruginosa — a high-priority pathogen according to the WHO, responsible for severe hospital-acquired infections. This vaccine aims to protect vulnerable individuals, especially those living with cystic fibrosis. Continue reading…
Press Releases
Université Laval and Glycovax Pharma Enter into an Exclusive Global Licens Agreement for the Development of Innovative Galectin-3 Inhibitors
Montréal and Québec City, 22 April 2026 — Université Laval and Glycovax Pharma announce an exclusive global license agreement granting Glycovax the rights to develop and commercialize a family of compounds targeting galectin-3, a cellular protein involved in multiple biological processes and recognized for its role in the development of numerous fibrotic diseases and other…
Glycovax Pharma, the National Research Council of Canada and the Université de Montréal, join forces to develop an innovative vaccine against the bacterium Pseudomonas aeruginosa (Pa), made possible through CQDM’s financial support
Fighting respiratory diseases, particularly in hospitals Montréal, Canada – October 8, 2025 – Glycovax Pharma today announced a strategic collaboration with the National Research Council of Canada (NRC) and the Faculty of Veterinary Medicine at the Université de Montréal to develop a glycoconjugate vaccine against Pseudomonas aeruginosa (Pa) infections. Funding for this project is made…
Glycovax Pharma is granted a licence by the National Research Council of Canada to develop a vaccine to fight nosocomial disease related to Pseudomonas aeruginosa (Pa)infections
Montreal, Canada, August 18, 2025 – Pseudomonas aeruginosa (Pa) is a bacterium responsible for nosocomial infections and is often fatal when contracted by people living with cystic fibrosis. There is currently no vaccine to prevent Pa-related infections even though this bacterium is a high-priority target for the World Health Organization (WHO). The National Research Council…
Media Centre
Looking for Glycovax Pharma in the media assets? The media centre shares news on the Company's products, research and corporate activities.
Media Contact
About Glycovax Pharma
Founded in Montreal, Canada, in 2016, Glycovax Pharma is a biopharmaceutical company specializing in the design and development of semi-synthetic vaccines. With its unique expertise in glycoimmunology, Glycovax Pharma is at the forefront of more effective vaccine solutions, particularly in the fields of viral, bacterial and cancer infections. For more information, visit: www.glycovax.com
Leadership
Discover Glycovax Pharma's leadership team committed to innovation and excellence in vaccine development. Learn more.
Technology
Learn how Glycovax Pharma’s cutting-edge platform of synthetic antigens, linkers, and adjuvants is shaping next-gen vaccines. Explore our technology to see innovation in action. Learn more.